Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease
Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…The long-term effect of continuous apomorphine treatment on camptocormia in Parkinson´s disease: a 24-months longitudinal open, prospective follow-up study
Objective: The aim of the study was to assess the long-term effect of subcutaneous infusions of apomorphine in the treatment of camptocormia in advanced Parkinson's…Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection
Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…Patient’s Choice of Device-Based Treatments in Parkinson’s Disease
Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Alternative Apomorphine Challenge Test
Objective: To propose a new apomorphine challenge test Background: In the standard apomorphine challenge test, the appropriate dose of apomorphine is established by incremental dosing…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »